EZH2 and neoplasm: In a recent paper, Xiao and co-workers furthermore identified the histone lysine-N-methyltransferase EZH2 as a possible epigenetic regulator of tumor response to AR-targeting therapy and demonstrated possibilities with its inhibition in the treatment of CRPC [44].